Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of September 2025, with a report date of September 22, 2025. The filing serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a global leader in consumer health with a portfolio spanning oral health, vitamins, pain relief, respiratory health, digestive health, and therapeutic skin health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes and Transactions
The filing details two specific transactions executed on September 18, 2025, on the London Stock Exchange (XLON) involving the acquisition of ordinary shares via dividend reinvestment:
- Tamara Rogers (Chief Marketing Officer): Acquired 5 shares at a price of £3.441 per share.
- Alan Stewart (Independent Non-Executive Director): Acquired 214 shares at a price of £3.424442 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly limited to the disclosure of PDMR shareholding changes.
Investor Verification Checklist
- Verify the total shareholding positions of Tamara Rogers and Alan Stewart following these transactions.
- Confirm the dividend reinvestment plan terms applicable to these acquisitions.
- Review the company's most recent Form 20-F or quarterly earnings release for actual financial performance metrics, as they are absent in this filing.